Metastatic Disease
32
1
1
13
Key Insights
Highlights
Success Rate
54% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
34.4%
11 terminated out of 32 trials
54.2%
-32.3% vs benchmark
3%
1 trials in Phase 3/4
54%
7 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (32)
Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
OLIGO-10: Stereotactic Ablative Radiation Therapy for Metastatic Patients With 6 to 10 Metastatic Sites
IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study
MAnagement of METastatic Disease in Campania (MAMETIC)
CPCT-02 Biopsy Protocol
The Role of Surgery for Esophageal Cancer With Metastatic Disease (M1)
Safety and Targeting of Anti-hk2 Antibody in mCRPC
Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.
Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial
Intravenously Administered Liposomal PROMITIL in Combination With External Beam Radiotherapy in Cancer Patients
Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
Stereotactic Radiation Therapy for Pediatric Sarcomas
The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies
Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer
Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy
Negative Pressure Wound Therapy vs. Sterile Dressing for Patients Undergoing Thoracolumbar Spine Surgery
Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary
CPCT-05 Biopsy Protocol Patient Selection
A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 Placebo